Product Information
DROSP-EE-LEVOMEF 3-0.02-0.451 is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $1.3823 per EA under NDC 68180089473. Its NADAC has been published 295 times since Feb 10, 2021.
FDA first approved this application on Jun 13, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
DROSP-EE-LEVOMEF 3-0.02-0.451
drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calciumManufacturer
Lupin Pharmaceuticals Inc.NDC
68180089473
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205947FDA Approved
6/13/2018
TE Code
AB
On Market Since
8/22/2018
Price Statistics
The NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has been published 295 times since Feb 10, 2021, and over the history we have for it it has declined 62.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3823 per EA |
|---|---|
| All-time high | $4.5285 (Apr 13, 2022) |
| All-time low | $1.2304 (Jul 17, 2024) |
| 52-week high | $1.6322 |
| 52-week low | $1.2523 |
| Median price | $2.4069 |
| Average price | $2.3741 |
| Largest weekly change | -47.8% (Apr 17, 2024) |
| Weeks tracked | 295 |
| Tracking since | Feb 10, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DROSP-EE-LEVOMEF 3-0.02-0.451?
The current National Average Drug Acquisition Cost (NADAC) for DROSP-EE-LEVOMEF 3-0.02-0.451, manufactured by Lupin Pharmaceuticals Inc., is $1.3823 per EA (NDC 68180089473), effective Sep 30, 2026.
How has the price of DROSP-EE-LEVOMEF 3-0.02-0.451 changed over time?
Over the history we have for it, the NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has declined 62.7%. It has been tracked across 295 weekly CMS publications since Feb 10, 2021.
What are the highest and lowest recorded NADAC prices for DROSP-EE-LEVOMEF 3-0.02-0.451?
Since Feb 10, 2021, the NADAC for DROSP-EE-LEVOMEF 3-0.02-0.451 has ranged from a low of $1.2304 (Jul 17, 2024) to a high of $4.5285 (Apr 13, 2022), with a median of $2.4069 per EA.
Are there cheaper alternatives to DROSP-EE-LEVOMEF 3-0.02-0.451?
No other NADAC-published product currently shares the active ingredient and strength of DROSP-EE-LEVOMEF 3-0.02-0.451 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DROSP-EE-LEVOMEF 3-0.02-0.451?
DROSP-EE-LEVOMEF 3-0.02-0.451 (NDC 68180089473) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.